1 option
CADTH Canadian Drug Expert Committee recommendation : indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Drugs--History.
- Drugs.
- Physical Description:
- 1 online resource
- Edition:
- First edition.
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2017.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.